Indian drug maker Cadila Healthcare Ltd said on Monday it had set up a wholly-owned unit in Japan to sell generic drugs.
The unit, Zydus Pharma Inc, will initiate a process for registration of products in 2007 and explore collaborations with Japanese drug firms in areas including research and development, marketing, contract manufacturing and formulations.
The company will be based in Shinjuku-ku, Tokyo, a statement from Cadila said.
Japan is the world's second-largest pharmaceutical market but has one of the lowest rates of generics consumption. A new prescription method was adopted from April to enhance the use of lower-cost generic drugs.
Shares in Cadila were up 1.18 per cent at Rs 339.65 at 0755 GMT in a firm Mumbai market.